Palbociclib or Ribociclib in First-Line Treatment in Patients With Hormone Receptor–Positive/Human Epidermal Receptor 2–Negative Advanced or Metastatic Breast Cancer? A Perspective Based on Pharmacologic Costs |
| |
摘 要: |
|
收稿时间: | 19 November 2018 |
本文献已被 ScienceDirect 等数据库收录! |
|